Clinical Trials in Pittsburgh, PA

Browse 97 Pittsburgh Medical Studies Across 778 Cities
43 Phase 3 Trial · 4301 Pittsburgh Clinics

Display Results

AllMost EffectiveMost SafeSenior FriendlyPediatricNo Placebo

Clinical Trials Clinical Trials in Pittsburgh, PA

Reviewed by Michael Gill, B. Sc.

Image of Comprehensive Cancer Centers of Nevada ( Site 0142) in Las Vegas, United States.

10 Pittsburgh Clinical Trials Near Me

Top Cities for Pittsburgh Clinical Trials

Pittsburgh

93Active Trials

University of Pittsburgh Medical CenterTop Active Site

Los Angeles

73Active Trials

Los Angeles County-USC Medical CenterTop Active Site

Pittsburgh Clinical Trials by Phase of Trial

N/A Pittsburgh Clinical Trials

12Active Pittsburgh Clinical Trials

12Number of Unique Treatments

352Number of Active Locations

Yoga-based Exercise (YE)Optimal Medical Care Portico transcatheter aortic valve HCMA-EBQI-LC DBS of the NAc Delayed Intervention MitraClip™ device implantation Telemetric Intervention regional nodal XRT Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System Buoy Electrolyte Drops Merit WRAPSODY Endovascular Stent Graft

Most Recent Pittsburgh Clinical Trials

Clinical Trial

Began Recruiting Date

Phase

IPH5201 + durvalumab + standard chemotherapy for Non-Small Cell Lung Cancer

6/23/2023

Phase 2

Arm B (ABVD, brentuximab vedotin, nivolumab) for Hodgkin's Lymphoma

5/11/2023

Phase 3

Step 1 : SPVN06 dose 1 for Retinitis Pigmentosa

4/12/2023

Phase 1 & 2

ARM B (ramucirumab, pembrolizumab) for Non-Small Cell Lung Cancer

3/14/2023

Phase 3

ITR + ELAPRASE for Hunter Syndrome

2/28/2023

Phase 4

About The Author

Michael Gill - B. Sc.

First Published: October 22nd, 2021

Last Reviewed: September 11th, 2023

References¹ Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2. https://pubmed.ncbi.nlm.nih.gov/34473343² Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9:CD013825. doi: 10.1002/14651858.CD013825.pub2. Review. https://pubmed.ncbi.nlm.nih.gov/34473343³ Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038. https://pubmed.ncbi.nlm.nih.gov/32171076⁴ Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum In: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038. https://pubmed.ncbi.nlm.nih.gov/32171076⁵ Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14. Review. https://pubmed.ncbi.nlm.nih.gov/31401903⁶ Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14. https://pubmed.ncbi.nlm.nih.gov/31401903⁷ Mellon L, Doyle F, Hickey A, Ward KD, de Freitas DG, McCormick PA, O'Connell O, Conlon P. Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients. Cochrane Database Syst Rev. 2022 Sep 12;9:CD012854. doi: 10.1002/14651858.CD012854.pub2. Review. https://pubmed.ncbi.nlm.nih.gov/36094829⁸ Mellon L, Doyle F, Hickey A, Ward KD, de Freitas DG, McCormick PA, O'Connell O, Conlon P. Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients. Cochrane Database Syst Rev. 2022 Sep 12;9(9):CD012854. doi: 10.1002/14651858.CD012854.pub2. https://pubmed.ncbi.nlm.nih.gov/36094829⁹ Flumignan RL, Tinôco JDS, Pascoal PI, Areias LL, Cossi MS, Fernandes MI, Costa IK, Souza L, Matar CF, Tendal B, Trevisani VF, Atallah ÁN, Nakano LC. Prophylactic anticoagulants for people hospitalised with COVID-19. Cochrane Database Syst Rev. 2020 Oct 2;10:CD013739. doi: 10.1002/14651858.CD013739. https://pubmed.ncbi.nlm.nih.gov/33502773¹⁰ Flumignan RL, Tinôco JDS, Pascoal PI, Areias LL, Cossi MS, Fernandes MI, Costa IK, Souza L, Matar CF, Tendal B, Trevisani VF, Atallah ÁN, Nakano LC. Prophylactic anticoagulants for people hospitalised with COVID-19. Cochrane Database Syst Rev. 2020 Oct 2;10:CD013739. doi: 10.1002/14651858.CD013739. Update in: Cochrane Database Syst Rev. 2022 Mar 4;3:CD013739. https://pubmed.ncbi.nlm.nih.gov/33502773